Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Trial of CM-AT in Children With Autism (CM-AT)

This study has been completed.
Information provided by (Responsible Party):
Curemark Identifier:
First received: April 13, 2009
Last updated: March 16, 2017
Last verified: March 2017
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.

Condition Intervention Phase
Drug: CM-AT
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase III Randomized Double Blind Placebo Controlled Trial of CM-AT in Children With Autism

Further study details as provided by Curemark:

Primary Outcome Measures:
  • Evidence of changes in behavior scales associated with the core symptoms of autism [ Time Frame: Baseline, 14 days, 30 days, 60 days, 90 days ]

Secondary Outcome Measures:
  • Other key measures of behavior and quality of life associated with autism [ Time Frame: Baseline, 14 days, 30 days, 60 days, 90 days ]

Enrollment: 182
Study Start Date: May 2009
Study Completion Date: September 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: CM-AT
Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Placebo Comparator: 2
Placebo powder
Drug: Placebo
Single unit dose powder of non-active substance administered 3 times per day for 90 days

Detailed Description:
Autism is currently a significant cause of disability in the pediatric population. Treatment is based upon the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a powder taken three times a day.

Ages Eligible for Study:   3 Years to 8 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets the current Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR) diagnostic criteria for autistic disorder (AD)

Exclusion Criteria:

  • Patient weighing < 11kg (24.2 lbs.)
  • Demonstrated previous allergy to porcine (pork) products
  • Previous history of severe head trauma or stroke, seizure within one year of entering study or uncontrolled systemic disease
  • Diagnosis of: HIV, cerebral palsy, endocrine disorder, pancreatic disease
  • Within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion)
  • Use of of any stimulant medication must be discontinued 5 days prior to entering the study.
  • Subject must have a stable dose of SSRI's for at least 30 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00881452

United States, Arizona
Southwest Autism Research and Resource Center
Phoenix, Arizona, United States, 85006
United States, California
University of California, Davis, M.I.N.D. Institute
Sacramento, California, United States, 95817
University of California, San Francisco
San Francisco, California, United States, 94143
Neuropsychiatric Research Center of Orange County
Santa Ana, California, United States, 92701
United States, Florida
Lake Mary Pediatrics
Orange City, Florida, United States, 32763
United States, Georgia
Institute for Behavioral Medicine
Smyrna, Georgia, United States, 30080
United States, Illinois
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois, United States, 60169
United States, Louisiana
Louisiana State University Health Science Center
Shreveport, Louisiana, United States, 71103
United States, New Jersey
Saint Peters University Hospital
New Brunswick, New Jersey, United States, 08901
United States, New York
Mount Sinai School of Medicine
NY, New York, United States, 10029
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27514
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
United States, Oklahoma
Oklahoma University Child Study Center
Oklahoma City, Oklahoma, United States, 73117
United States, Oregon
Cyn3rgy Research
Gresham, Oregon, United States, 97030
United States, Pennsylvania
Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Drexel University
Philadelphia, Pennsylvania, United States, 19124
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15260
United States, Texas
University of Texas, Houston
Houston, Texas, United States, 77054
United States, Utah
Westside Medical
Clinton, Utah, United States, 84015
Sponsors and Collaborators
Principal Investigator: Eugene Arnold, MD MEd. Nisonger Center Ohio State University
  More Information


Responsible Party: Curemark Identifier: NCT00881452     History of Changes
Other Study ID Numbers: 00101
Study First Received: April 13, 2009
Last Updated: March 16, 2017

Keywords provided by Curemark:

Additional relevant MeSH terms:
Autistic Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders processed this record on April 27, 2017